Read up on our latest news

Featured Story

Mirvie Founders
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Stst Logo
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Mirvie Founders

Media Coverage

press logo
Mirvie's RNA platform revolutionizes detection of fetal growth restriction
February 4, 2025
Discover how Mirvie’s RNA platform uses a simple blood test to detect fetal growth restriction early in pregnancy, allowing for proactive interventions and improved outcomes for mothers and babies.
Read more
press logo
Mirvie’s RNA Platform Shows Promise in Predicting Severe Fetal Growth Restriction
January 31, 2025
Mirvie has announced new research demonstrating its RNA platform’s ability to predict severe fetal growth restriction months before delivery
Read more
press logo
RNA Molecular Signal of Severe Fetal Growth Restriction Found by Mirvie
January 30, 2025
According to new data, Mirvie’s RNA platform can predict which unborn babies have severe growth restriction—a leading cause of stillbirth—far more accurately than current methods.
Read more
press logo
Mirvie's technology can now predict severe growth restriction in pregnancy - a leading cause of stillbirth
January 30, 2025
Mirvie RNA platform first to uncover a unique molecular signal for babies at risk
Read more
press logo
Interview: On the hunt for the earliest signs of high-risk pregnancies
January 30, 2025
Californian biotech firm Mirvie is pioneering a new approach to high risk pregnancies, by tracking a unique molecular signal associated with a leading cause of stillbirth.
Read more
press logo
Q&A: RNA platform predicts severe fetal growth restriction months before birth
January 30, 2025
Using Mirvie’s unique RNA platform is starting to expedite the amount of conditions we can identify very early in the pregnancy to help identify those at most risk
Read more
press logo
Venture capital firms making bets on maternal health
August 19, 2024
"Saving the lives of mothers and babies is in everyone's interest, so for breakthrough innovations like Mirvie and Vitara, there is a lot of space to obtain reimbursement," said Alex Morgan, a partner at Khosla Ventures.
Read more
press logo
The silent epidemic within the maternal health crisis
September 25, 2024
Screening tests like (Mirvie's) offer tremendous value to everyone involved, from the doctor and care team to the mom and her unborn child. Identifying those most at risk for complications will allow for early intervention, when every action possible can be taken to create a healthy pregnancy.
Read more
press logo
Why biology is catalyzing breakthroughs in women’s health
December 10, 2024
The new wave of startups in this area are focused on advancing the field to better serve women.
Read more
press logo
Birthing mothers’ near-death experience rates are 100 times higher than maternal mortality—and we don’t even know exactly why
May 10, 2024
We need more support to create a world where every pregnancy is as healthy and as safe as possible.
Read more
A personalized window
into pregnancy health.
650-741-6510
651 Gateway Boulevard, Suite 1200
South San Francisco, California 94080
References
Terms of Service
Privacy Policy
©2025 Mirvie, Inc. All rights reserved.